Novotech Honored with Frost & Sullivan’s 2024 Best Practices Company of the Year Award for Leadership in Biotech CRO Services
10.9.2024 22:20:00 EEST | Business Wire | Press release
Novotech, the global full-service clinical Contract Research Organization (CRO), is proud to announce that it has been awarded the prestigious 2024 Global Company of the Year Award by Frost & Sullivan. This recognition underscores Novotech’s commitment to accelerating clinical development for biotech companies through innovative solutions, advanced analytics, and a comprehensive global reach.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240910876910/en/
(Graphic: Business Wire)
Frost & Sullivan’s award honors Novotech’s innovative full-service approach that accelerates clinical development through advanced analytics, access to diverse patient populations, and through specialized technology.
“Overall, Novotech distinguishes itself in the ever-expanding CRO market by successfully addressing the complex regulatory landscape with a deep understanding of local regulations and overcoming cultural barriers to establish itself as a truly global CRO. As a result, the company progresses closer to becoming a preferred global partner with regional leadership and localized expertise,” said Unmesh Lal, Global Research Director at Frost & Sullivan.
Unmatched Global Reach and Expertise
Novotech's extensive global footprint allows the company to provide tailored solutions that address the unique regulatory and cultural nuances of each market. This strategic advantage facilitates faster patient recruitment and enhanced trial efficiency, ensuring successful outcomes for its biotech clients. Novotech's project manager-centric model ensures seamless communication and effective execution of clinical trials, fostering strong, collaborative relationships with clients.
Commitment to Innovation and Advanced Technology
A key element in being awarded this accolade is Novotech continuing to leverage cutting-edge technology to enhance clinical trial operations. The company's ongoing investments in artificial intelligence (AI), big data analytics, digital clinical trials, and cloud-based software platforms significantly improve data quality, trial planning, and transparency in communications with stakeholders. Partnerships with industry leaders like Veeva and Medidata further empower Novotech’s clients to optimize their drug development programs.
Recognition of Excellence
Frost & Sullivan first recognized Novotech with their award for best APAC CRO in 2006, and Novotech has continued to win this award every year since. Receiving, for the first time, Frost & Sullivan’s 2024 Global Company of the Year Award is tangible evidence of Novotech’s drive for constant improvement and creating optimal outcomes for our partners and clients.
“We are honored to receive the 2024 Global Company of the Year Award from Frost & Sullivan,” said Dr. John Moller, CEO of Novotech. “This recognition is a testament to the hard work and dedication of our team, our commitment to innovation, and our unwavering focus on delivering exceptional results for our biotech and pharmaceutical clients. We are proud to be at the forefront of advancing clinical development and to be acknowledged as a leader in the CRO industry.”
Frost & Sullivan Best Practices Awards recognize companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry.
About NovotechNovotech-CRO.com
Founded in 1997, Novotech is a global full-service clinical Contract Research Organization (CRO) focused on partnering with biotech companies to accelerate the development of advanced and novel therapeutics at every phase.
Recognized for its industry-leading contributions, Novotech has received numerous prestigious awards, including the CRO Leadership Award 2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023, the Asia-Pacific Contract Research Organization Company of the Year Award since 2006.
The Company offers a comprehensive suite of services including laboratories, Phase I facilities, drug development consulting, regulatory expertise, and has experience with over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. With a presence in 34 office locations and a dedicated team of 3,000+ professionals worldwide, Novotech is a trusted end-to-end strategic partner of choice.
For more information or to speak to an expert team member visit www.Novotech-CRO.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20240910876910/en/
Contacts
Media
Toyna Chin
mediacontact@novotech-cro.com
USA: +1 415 364 8135
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Horizon3 Earns Cyber Essentials Certification Covering NodeZero EU Network28.9.2026 11:00:00 EEST | Press release
Horizon3, the AI-Native Proactive Security Company, today announced that it has earned Cyber Essentials Plus certification covering its NodeZero AWS EU network. The network supports Horizon3’s EU data sovereignty site in Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260928143792/en/ Horizon3 Earns Cyber Essentials Certification Covering NodeZero EU Network Organizations use NodeZero® to test production environments and find weaknesses attackers can exploit. When customers and partners assess the platform itself, they also need to understand the security standards applied to its supporting infrastructure. The Cyber Essentials certificate identifies a defined portion of that infrastructure and the baseline against which it was assessed. Developed by the UK’s National Cyber Security Centre, Cyber Essentials addresses five foundational controls: firewalls, secure configuration, security updates, user access control, an
Thales Expands Collaboration with Google Cloud to Help Secure Agentic AI Workflows28.9.2026 10:03:00 EEST | Press release
Thales today announced an expanded collaboration with Google Cloud to help enterprises address emerging security and governance challenges associated with agentic AI, bringing integrated protection, visibility, and policy enforcement to AI-driven workflows on Google Cloud. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260928647188/en/ ©Thales The integration of Thales AI Security Fabric with Google Cloud Gemini Enterprise helps organizations apply security, governance, and visibility across interactions among users, agents, models, and tools in real time. “Enterprises are moving from AI assistants to AI agents that can autonomously take action, make decisions, and interact with critical business systems. This requires a fundamentally different approach to security,” Eva Rudin, Senior Vice President, Cybersecurity Products, at Thales, said.“By expanding our collaboration with Google Cloud, we are helping organizations build
SPORVIGILANCE Targets Safer Medicines and Billion-Euro Savings for Global Pharma Facing EU IDMP Fines28.9.2026 09:13:00 EEST | Press release
British regulatory technology company SPORVIGILANCE is targeting one of global pharma’s major compliance challenges with a platform offering a faster route to IDMP and SPOR readiness, compliance and governance. As the European Medicines Agency advances structured medicinal product data, companies face pressure to keep regulatory data accurate, standardised and aligned with EMA requirements. SPORVIGILANCE replaces fragmented manual assessment with a regulatory intelligence layer built around IDMP, SPOR and Product Management Service (PMS) requirements. At its core is an IDMP Business Rule Validation Engine that assesses medicinal product data at scale and at field level, identifying missing, inconsistent and non-compliant data. SPORVIGILANCE is the only platform to translate IDMP business rules directly into automated validation logic, enabling companies to test data against the rules rather than rely on manual interpretation. Its PMS Alignment capability reconciles internal RIM data ag
Sofinnova Partners Closes Oversubscribed €82 Million Sofinnova MD Start IV Fund to Create the Next Generation of Medtech Companies28.9.2026 09:00:00 EEST | Press release
Sofinnova Partners ("Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced the final close of Sofinnova MD Start IV at €82 million. The fund, which was oversubscribed, will help expand Sofinnova's medtech company-creation strategy across Europe and the US with greater capacity to launch new ventures and support them through key stages of development. With plans to launch six to eight new medtech companies over the next five years, Sofinnova MD Start IV will support ventures from inception through key clinical and operational milestones, providing founders with both capital and hands-on support. Sofinnova MD Start's approach combines clinical insight, entrepreneurial talent, and operational expertise to tackle significant unmet medical needs. The previous fund, Sofinnova MD Start III, a €63 million fund, invested across six companies that have collectively raised more than €140 million in follow-on financing. Sofinnova MD S
Ant International’s Antom Upgrades Southeast Asia Leadership Structure to Drive Regional Synergy in the AI Era28.9.2026 08:18:00 EEST | Press release
Antom, a leading merchant payment and digitisation services provider under Ant International, today announced a series of key appointments for its operations in Southeast Asia to further strengthen the synergy among its regional brands and better serve regional merchants with streamlined full-stack AI-native solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260927431282/en/ Nabilah Alsagoff, co-founder and former chief operating officer of DOKU, Indonesia's leading payment fintech company, has been appointed as Head of Product, Antom SEA. In her new role, the payment veteran will oversee product development and innovation and drive a unified product roadmap for the overall SEA region. Chris Yeo, former chief executive officer (CEO) of DOKU, will take on the role as Head of Antom Philippines, and Country Head of 2C2P Philippines. With his long experience at DOKU, Grab and PayPal, Chris will also oversee the execution
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom